Cargando…

P2Y12 blocker monotherapy after percutaneous coronary intervention

For secondary prevention of coronary artery disease (CAD) antiplatelet therapy is essential. For patients undergoing a percutaneous coronary intervention (PCI) temporary dual antiplatelet platelet therapy (DAPT: aspirin combined with a P2Y12 blocker) is mandatory, but leads to more bleeding than sin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Verheugt, F. W. A., Damman, P., Damen, S. A. J., Wykrzykowska, J. J., Woelders, E. C. I., van Geuns, R. -J. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bohn Stafleu van Loghum 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556441/ https://www.ncbi.nlm.nih.gov/pubmed/34101134 http://dx.doi.org/10.1007/s12471-021-01582-7

Ejemplares similares

P2Y(12) Inhibitor Monotherapy after Percutaneous Coronary Intervention
por: Zhou, Xuan, et al.
Publicado: (2022)

The efficacy and safety of P2Y12 inhibitor monotherapy in patients after percutaneous coronary intervention
por: Luo, Liman, et al.
Publicado: (2019)

P2Y12 Inhibitor Monotherapy with Clopidogrel versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
por: Chen, Po-Wei, et al.
Publicado: (2020)

Recommendations for the use of bioresorbable vascular scaffolds in percutaneous coronary interventions: 2017 revision
por: Everaert, B., et al.
Publicado: (2017)

P2Y12 inhibitor monotherapy after complex percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials
por: Sotomi, Yohei, et al.
Publicado: (2023)

P2Y12 Inhibitor Monotherapy versus Conventional Dual Antiplatelet Therapy in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: A Meta-Analysis
por: Feng, Wen-Han, et al.
Publicado: (2023)

Sex-Based Outcomes of P2Y12 Inhibitor Monotherapy After Three Months of Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention
por: Shin, Eun-Seok, et al.
Publicado: (2023)

P2Y(12) inhibitor monotherapy in complex percutaneous coronary intervention: A post-hoc analysis of SMART-CHOICE randomized clinical trial
por: Roh, Ji Woong, et al.
Publicado: (2021)

Antiplatelet and anticoagulant therapy in elective percutaneous coronary intervention
por: ten Berg, Jurriën M, et al.
Publicado: (2001)

P2Y(12) Platelet Receptors: Importance in Percutaneous Coronary Intervention
por: Falcão, Felipe Jose de Andrade, et al.
Publicado: (2013)

Comparative Efficacy and Safety of P2Y12 Inhibitor Monotherapy and Dual Antiplatelet Therapy in Patients with and without Diabetes Mellitus Undergoing Percutaneous Coronary Intervention
por: Feng, Wen-Han, et al.
Publicado: (2022)

Intolerance to Multiple P2Y12 Inhibitors Following Percutaneous Coronary Intervention
por: Shnoda, Mina, et al.
Publicado: (2021)

Premedication to reduce anxiety in patients undergoing coronary angiography and percutaneous coronary intervention
por: Vlastra, Wieneke, et al.
Publicado: (2018)

De-escalation of P2Y12 Inhibitor Use After Percutaneous Coronary Intervention and Acute Coronary Syndromes
por: Barry, Quinton, et al.
Publicado: (2021)

Long-Term Beta-Blocker Therapy in Patients With Stable Coronary Artery Disease After Percutaneous Coronary Intervention
por: Lee, Seung-Jun, et al.
Publicado: (2022)

The Clinical Impact of β-Blocker Therapy on Patients With Chronic Coronary Artery Disease After Percutaneous Coronary Intervention
por: Park, Jiesuck, et al.
Publicado: (2022)

Ivabradine in Combination with Beta-Blockers in Patients with Chronic Stable Angina After Percutaneous Coronary Intervention
por: Werdan, Karl, et al.
Publicado: (2015)

Pharmacodynamic Comparison of Ticagrelor Monotherapy Versus Ticagrelor and Aspirin in Patients After Percutaneous Coronary Intervention: The TEMPLATE (Ticagrelor Monotherapy and Platelet Reactivity) Randomized Controlled Trial
por: Johnson, Thomas W., et al.
Publicado: (2020)

Tailoring P2Y(12) Inhibiting Therapy in Elderly Patients With Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
por: Capranzano, Piera, et al.
Publicado: (2019)

Multifaceted Intervention to Improve P2Y12 Inhibitor Adherence After Percutaneous Coronary Intervention: A Stepped Wedge Trial
por: Ho, P. Michael, et al.
Publicado: (2022)

Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Percutaneous Coronary Intervention: A Meta‐Analysis
por: Gelbenegger, Georg, et al.
Publicado: (2021)

Cost-Effectiveness of Clopidogrel vs Aspirin Monotherapy After Percutaneous Coronary Intervention: Results From the HOST-EXAM Study
por: Hwang, Doyeon, et al.
Publicado: (2023)

De-Escalation of P2Y(12) Receptor Inhibitor Therapy after Acute Coronary Syndromes in Patients Undergoing Percutaneous Coronary Intervention
por: Kupka, Danny, et al.
Publicado: (2018)

Comparative Risk of Hospitalized Bleeding of P2Y12 Inhibitors for Secondary Prophylaxis in Acute Coronary Syndrome After Percutaneous Coronary Intervention
por: Kumar, Arun, et al.
Publicado: (2022)

Feasibility and safety of cangrelor in patients with suboptimal P2Y(12) inhibition undergoing percutaneous coronary intervention: rationale of the Dutch Cangrelor Registry
por: Selvarajah, A., et al.
Publicado: (2021)

P2y(12) inhibitor monotherapy after 1–3 months dual antiplatelet therapy in patients with coronary artery disease and chronic kidney disease undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials
por: Yu, Yanqiao, et al.
Publicado: (2023)

Appropriate use criteria for optical coherence tomography guidance in percutaneous coronary interventions: Recommendations of the working group of interventional cardiology of the Netherlands Society of Cardiology
por: IJsselmuiden, A. J. J., et al.
Publicado: (2018)

The effects of prior calcium channel blocker therapy on creatine kinase-MB levels after percutaneous coronary interventions
por: Gulmez, Oyku, et al.
Publicado: (2008)

Long‐term impact of β‐blocker in elderly patients without myocardial infarction after percutaneous coronary intervention
por: Fukase, Tatsuya, et al.
Publicado: (2021)

Adoption of prasugrel into routine practice: rationale and design of the Rijnmond Collective Cardiology Research (CCR) study in percutaneous coronary intervention for acute coronary syndromes
por: Yetgin, T., et al.
Publicado: (2013)

Long-term Outcomes of Clopidogrel Monotherapy versus Prolonged Dual Antiplatelet Therapy beyond 12 Months after Percutaneous Coronary Intervention in High-risk Patients
por: Kim, Dong-Yeon, et al.
Publicado: (2021)

Early intravenous beta-blockers in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: A patient-pooled meta-analysis of randomized clinical trials
por: Hoedemaker, Niels PG, et al.
Publicado: (2019)

Risks and benefits of percutaneous coronary intervention in spontaneous coronary artery dissection
por: Kotecha, Deevia, et al.
Publicado: (2021)

Impact of residual angina on long-term clinical outcomes after percutaneous coronary intervention or coronary artery bypass graft for complex coronary artery disease
por: Ono, Masafumi, et al.
Publicado: (2022)

Feasibility and safety of cangrelor in patients with suboptimal P2Y(12) inhibition undergoing percutaneous coronary intervention: the Dutch Cangrelor registry
por: Selvarajah, Abi, et al.
Publicado: (2021)

Appropriate use of bioresorbable vascular scaffolds in percutaneous coronary interventions: a recommendation from experienced users: A position statement on the use of bioresorbable vascular scaffolds in the Netherlands
por: Everaert, Bert, et al.
Publicado: (2015)

P2Y12 platelet inhibition in clinical practice
por: Damman, Peter, et al.
Publicado: (2011)

Differences in Optimal Platelet Reactivity after Potent P2Y12 Inhibitor Treatment in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention
por: Song, Kai, et al.
Publicado: (2022)

Bivalirudin in percutaneous coronary intervention
por: Lehman, Sam J, et al.
Publicado: (2006)

Relationship Between β‐Blocker Therapy at Discharge and Clinical Outcomes in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
por: Li, Chenze, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_72c295glmladvhnqr6jhv94j1r